ClinicalTrials.gg
CompletedNCT01802281SUPeRUpdated Aug 26, 2025Results posted

Study of Uterine Prolapse Procedures - Randomized Trial

An interventional study of Uterosacral ligament suspension and Uphold® LITE in Uterovaginal Prolapse, sponsored by NICHD Pelvic Floor Disorders Network. Completed at 8 sites in United States. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by NICHD Pelvic Floor Disorders Network · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
21 Years and older
Sex
Female
01

Study summary

The primary purpose of this randomized clinical trial is to compare the effectiveness and safety of two transvaginal apical suspension strategies for uterovaginal prolapse: a mesh augmented hysteropexy versus vaginal hysterectomy and uterosacral ligament suspension (USLS). The primary aim is to determine whether treatment success in women who undergo the above strategies differ at time points through 3 years.

A supplemental study investigates anterior vaginal wall movement resulting from descent or rotation of the vaginal apex and/or anterior vaginal elongation, in women in both of the study arms of SUPeR.

Read the detailed description

The study population will be adult women (>21 years of age) with symptomatic uterovaginal prolapse at or beyond the hymen who desire vaginal surgical management. This study is intended to be done only on women who have completed child-bearing and have an inactive uterus, defined as amenorrhea for 1 year. Therefore women will be postmenopausal or will have amenorrhea from an endometrial ablation. Amenorrhea caused from exogenous steroids, or hypothalamic disorders will not allow inclusion.

Participants will be obtained from the clinic population of each of the eight Pelvic Floor Disorders Network (PFDN) sites. Participants will be randomly assigned to have either vaginal hysterectomy and USLS or mesh hysteropexy suspension for treatment of their uterovaginal prolapse. The surgical assignment will be revealed in the operating room, after the participant is under anesthesia.

Participants will be followed for at least 36-months (3-years) post surgery and up to a maximum of 60-months (5-years) during the primary trial. Participants who complete the primary trial will be approached for consent for long-term follow-up as part of a study extension and will be followed up to a maximum of 120-months (10-years). Follow-up data will be obtained during in-person clinic visits, and study staff who are masked to the surgical assignment will be the primary person who obtain follow-up data. Although the primary study outcome does not depend on masked participants and blinded evaluators, several important participant reported secondary aims are subject to reporting bias if the participant is aware of her study assignment. Therefore, study participants, coordinators, and nurses will be masked to the study assignment. Study surgeons and anatomic evaluators will be unmasked. Evaluators conducting the POPQ exam will be a co-investigator, fellow or other qualified nurse who did not perform the study surgery.

Surgical failure rates will be compared using survival analysis approaches appropriate for interval censored data (classic log-rank tests and survival models using a generalized linear model approach with a complementary log-log link) and secondary outcomes will be reported as rates in each group or as group means and evaluated with the appropriate parametric or nonparametric statistical tests.

Throughout the study, the PFDN Data Safety and Monitoring Committee (DSMB) will review study data and decide if the study can or cannot continue. Additionally, this study will adhere to the CONSORT guidelines for performing and reporting randomized controlled trials (Begg et al 1996). Women who are eligible but decline enrollment will be characterized in a manner consistent with CONSORT requirements.

02

Conditions studied

  • Uterovaginal Prolapse
03

In context

Lead sponsor

NICHD Pelvic Floor Disorders Network is the lead sponsor of 17 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women aged 21 or older who have completed child -bearing
  2. Prolapse beyond the hymen (defined as Ba, Bp, or C > 0 cm)
  3. Uterine descent into at least the lower half of the vagina (defined as point C> -TVL/2) )
  4. Bothersome bulge symptoms as indicated on question 3 of the PFDI-20 form relating to 'sensation of bulging' or 'something falling out'
  5. Desires vaginal surgical treatment for uterovaginal prolapse
  6. Available for up to 60 month follow-up
  7. Amenorrhea for the past 12 months from either menopause or endometrial ablation
  8. Not pregnant, not at risk for pregnancy or agree to if at risk for pregnancy (only applicable to the rare endometrial ablation patient)
  9. Eligible for no cervical cancer screening for at least 3 years

Exclusion criteria

Exclusion Criteria:

  1. Previous synthetic material (placed vaginally or abdominally) to augment POP repair
  2. Known previous uterosacral or sacrospinous uterine suspension
  3. Known adverse reaction to synthetic mesh or biological grafts; these complications include but are not limited to erosion, fistula, or abscess
  4. Chronic pelvic pain
  5. Pelvic radiation
  6. Cervical elongation- defined as an expectation that the C point would be Stage 2 or greater postoperatively if a hysteropexy was performed. (Note: cervical shortening or trachelectomy is not an allowed intraoperative procedure within the hysteropexy treatment group).
  7. Women at increased risk of cervical dysplasia requiring cervical cancer screening more often than every 3 years (e.g. + status, because of transplant related medications, Diethylstilbestrol (DES) exposure in utero, or previous treatment for cervical intraepithelial neoplasia (CIN)2, CIN3, or cancer)
  8. Uterine abnormalities (symptomatic uterine fibroids, polyps, endometrial hyperplasia, endometrial cancer, or any uterine disease that precluded prolapse repair with uterine preservation in the opinion of the surgeon
  9. Indication for ovarian removal (adnexal mass, BRCA 1/2 positivity, family history of ovarian cancer)
  10. Current condition of amenorrhea caused by exogenous sex or hypothalamic conditions.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
183 participants (actual)

Study arms

  • Active comparator
    Hysteropexy

    Uphold® LITE

    Procedure: Uphold® LITE

  • Active comparator
    Hysterectomy and USLS

    Vaginal hysterectomy and uterosacral ligament suspension (USLS)

    Procedure: Uterosacral ligament suspension

Interventions

  • ProcedureUterosacral ligament suspension

    The USLS procedure used in this protocol is a modification of the technique described by Shull.

  • ProcedureUphold® LITE

    The Uphold® procedure used in this protocol is a modification of the technique described by Vu and Goldberg.

06

What researchers measure

Primary outcomes

  1. Cumulative Failure

    Failure was defined as any of the following: retreatment for prolapse, any POP-Q measure beyond the hymen, or presence of bother on PFDI vaginal bulge question. Under the permanent failure state assumption, the number of participants shown at each visit includes all participants who were still participating in the study or had a failure outcome prior their withdrawal. Similarly, the denominator number of participants for the cumulative failure at each visit includes all participants who were still participating in the study and attended the visit or had any failure outcome prior their withdrawal or missed visit.

    Time frame: 6 Months through 36 Months

Secondary outcomes

  1. At-visit Failure

    Failure was defines as any of the following: retreatment for prolapse, any POP-Q measure beyond the hymen, or presence of bother on PFDI vaginal bulge question. Under the transient failure state assumption, the number of participants shown at each visit includes all participants who were still participating in the study. Similarly, the denominator number of participants for the transient failure at each visit includes all participants who were still participating in the study and attended the visit or who missed the visit but had a retreatment failure outcome prior to their missed visit.

    Time frame: 6 months through 36 Months

Other outcomes

  1. Change From Baseline PFDI Score

    The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

    Time frame: 6, 12, 18, 24, and 36 Months

  2. Change From Baseline CRADI Score

    The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

    Time frame: 6, 12, 18, 24, and 36 Months

  3. Change From Baseline POPDI Score

    The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

    Time frame: 6, 12, 18, 24, and 36 Months

  4. Change From Baseline UDI Score

    The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

    Time frame: 6, 12, 18, 24, and 36 Months

  5. Change From Baseline PFIQ Score

    The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman''s daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

    Time frame: 6, 12, 18, 24, and 36 Months

  6. Change From Baseline CRAIQ Score

    The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman''s daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

    Time frame: 6, 12, 18, 24, and 36 Months

  7. Change From Baseline POPIQ Score

    The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman''s daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

    Time frame: 6, 12, 18, 24, and 36 Months

  8. Change From Baseline UIQ Score

    The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman''s daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

    Time frame: 6, 12, 18, 24, and 36 Months

  9. Change From Baseline Incontinence Severity Index

    Incontinence Severity Index measuring the severity of urinary incontinence is composed of 2 questions: frequency of leakage (0=Never,...,4=Every day/night) and amount of urine leakage (1=Drops, 2=small splashes, 3= More). The index score is calculated categorizing the product of the two responses. The range of responses is: 0 (no incontinence) to 12 (severe incontinence). Lower index scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

    Time frame: 6, 12, 18, 24, and 36 Months

  10. Change From Baseline Functional Activity Scale

    Functional Activity Scale measuring the impact of incontinence symptoms on a woman''s daily activities is composed of 13 questions about normal and physically strenuous daily activities. The range of responses on the individual questions is (1) No difficulty,... (5) Not able to do it. Scores are calculated by subtracting from the maximum sum (5\*13=65) the product of the mean response and number of questions, then dividing by the total range of sums (65 - 13 = 52) and multiplying by 100. The range of responses is: 0-100 with 0 (worse functionality) to 100 (Better functionality). Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

    Time frame: 6, 12, 18, 24, and 36 Months

  11. Change From Baseline Body Part Pain Scale

    The Body Part Pain Scale measuring the the pain experienced in the lower abdomen and pelvic region of the body is composed of 7 questions, each with a yes (1) or no (0) questions about experiencing pain followed by an intensity rating: 0 (No pain),..., 10 (Most intense). The score is calculated as the average of the responses. The range of responses is: 0-10 with 0 (No pain) to 10 (most intense pain). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

    Time frame: 6, 12, 18, 24, 30, and 36 Months

  12. Change From Baseline Surgical Pain Scale Rest Score

    The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

    Time frame: 6, 12, 18, 24, and 36 Months

  13. Change From Baseline Surgical Pain Scale Normal Score

    The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

    Time frame: 6, 12, 18, 24, and 36 Months

  14. Change From Baseline Surgical Pain Scale Exercise Score

    The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

    Time frame: 6, 12, 18, 24, and 36 Months

  15. Change From Baseline Surgical Pain Scale Worst Score

    The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

    Time frame: 6, 12, 18, 24, and 36 Months

  16. Change From Baseline Body Image Scale

    The Body Image Scale measuring how the subjects feel about their appearance and about any changes that may have resulted from their condition consists of 8 questions. The questions are scored from 0=Not at all,..., 3=Very much. The score is calculated by summing the responses and ranges from 0 to 24. Higher scores correspond to worse body image. Change = Month \[6, 12, 18, 24, and 36\] Score - Baseline Score.

    Time frame: 6, 12, 18, 24, and 36 Months

  17. Change From Baseline PISQ-IR Sexually Active Average Score

    The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR) is a questionnaire measuring the impact of incontinence symptoms on sexual function and satisfaction. The PISQ-IR Sexually Active-Average Score (SA-AVG) ranges from 0 to 5 with higher scores indicating better function/satisfaction. The change from baseline outcome is calculated as the difference in score at 6, 12, 18, 24, and 36 months and the score at baseline.

    Time frame: 6, 12, 18, 24, and 36 Months

  18. POP-Q Ba Measurement

    The Pelvic Organ Prolapse Quantification (POPQ) Point Ba represents the most distal (i.e. most dependent) position of any part of the upper anterior vaginal wall (between the vaginal cuff or anterior vaginal fornix and Point Aa). Point Ba coincides with Point Aa (-3 cm) in a woman who has no anterior POP. In a woman with severe POP, Ba coincides with Point C.

    Time frame: 12, 24, and 36 Months

  19. POP-Q Bp Measurement

    The Pelvic Organ Prolapse Quantification (POPQ) Point Bp represents the most distal position of any part of the upper posterior vaginal wall (between the vaginal cuff or posterior vaginal fornix and Point Ap).

    Time frame: 12, 24, and 36 Months

  20. POP-Q C Measurement

    The Pelvic Organ Prolapse Quantification (POPQ) Point C is measured in cm relative to the hymen with negative values being proximal to the hymen and positive values distal to the hymen. Point C represents either the most distal edge of the cervix or the leading edge of the vaginal cuff after total hysterectomy.

    Time frame: 12, 24, and 36 Months

  21. POP-Q TVL Measurement

    The Pelvic Organ Prolapse Quantification (POPQ) Total Vaginal Length (TVL) is the length of the vagina from posterior fornix tothe hymen when Point C or D is reduced to its full normal position.

    Time frame: 12, 24, and 36 Months

  22. PGI-I

    The Patient Global Impression of Improvement (PGI-I) is a patient-reported measure of perceived improvement with treatment, as assessed on a scale of 1 (very much better) to 7 (very much worse). Included here are participants who had improvement as indicated by a rating of 1 (very much better), 2 (much better).

    Time frame: 6,12, 18, 24, and 36 Months

07

Results

Posted Mar 22, 2021

Participant flow

Participant flow — Overall Study
MilestoneHysteropexyHysterectomy and USLS
Started9390
Eligible and received randomized treatment8887
Completed year 1 follow-up8886
Completed year 2 follow-up8784
Completed8584
Not completed86
Withdrew: Death12
Withdrew: Withdrawal by subject21
Withdrew: Ineligible53

Outcome measures

PrimaryCumulative Failure

Failure was defined as any of the following: retreatment for prolapse, any POP-Q measure beyond the hymen, or presence of bother on PFDI vaginal bulge question. Under the permanent failure state assumption, the number of participants shown at each visit includes all participants who were still participating in the study or had a failure outcome prior their withdrawal. Similarly, the denominator number of participants for the cumulative failure at each visit includes all participants who were still participating in the study and attended the visit or had any failure outcome prior their withdrawal or missed visit.

Time frame:
6 Months through 36 Months
Reported as:
Count of participants · Participants
Cumulative Failure
ParticipantsUPHOLDUSLS
6 Months — Non-Failure7869
6 Months — Failure916
12 Months — Non-Failure7163
12 Months — Failure1522
18 Months — Non-Failure6658
18 Months — Failure1926
24 Months — Non-Failure5954
24 Months — Failure2129
30 Months — Non-Failure5552
30 Months — Failure2431
36 Months — Non-Failure5347
36 Months — Failure2634
SecondaryAt-visit Failure

Failure was defines as any of the following: retreatment for prolapse, any POP-Q measure beyond the hymen, or presence of bother on PFDI vaginal bulge question. Under the transient failure state assumption, the number of participants shown at each visit includes all participants who were still participating in the study. Similarly, the denominator number of participants for the transient failure at each visit includes all participants who were still participating in the study and attended the visit or who missed the visit but had a retreatment failure outcome prior to their missed visit.

Time frame:
6 months through 36 Months
Reported as:
Count of participants · Participants
At-visit Failure
ParticipantsUPHOLDUSLS
6 Months — Non-failure7869
6 Months — Failure916
12 Months — Non-failure7465
12 Months — Failure1219
18 Months — Non-failure6965
18 Months — Failure1518
24 Months — Non-failure6463
24 Months — Failure1517
30 Months — Non-failure6060
30 Months — Failure1818
36 Months — Non-failure6257
36 Months — Failure1621
Other pre-specifiedChange From Baseline PFDI Score

The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame:
6, 12, 18, 24, and 36 Months
Reported as:
Least squares mean · units on a scale
Change From Baseline PFDI Score
units on a scaleUPHOLDUSLS
6 Months-81.7 (-93.3 to -70.1)-73 (-84.8 to -61.1)
12 Months-81.2 (-92.9 to -69.6)-75.4 (-87.3 to -63.5)
18 Months-78.7 (-90.5 to -67)-75.8 (-87.8 to -63.9)
24 Months-82.1 (-93.9 to -70.2)-76.6 (-88.7 to -64.5)
36 Months-79.8 (-91.7 to -67.8)-80.1 (-92.3 to -67.8)
Other pre-specifiedChange From Baseline CRADI Score

The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame:
6, 12, 18, 24, and 36 Months
Reported as:
Least squares mean · units on a scale
Change From Baseline CRADI Score
units on a scaleUPHOLDUSLS
6 Months-11.5 (-15.6 to -7.4)-11.1 (-15.3 to -6.9)
12 Months-11.1 (-15.2 to -7)-11.2 (-15.4 to -7)
18 Months-10.6 (-14.8 to -6.5)-11.9 (-16.1 to -7.6)
24 Months-12.4 (-16.6 to -8.2)-11.4 (-15.7 to -7.2)
36 Months-11.4 (-15.6 to -7.2)-11.6 (-15.9 to -7.2)
Other pre-specifiedChange From Baseline POPDI Score

The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame:
6, 12, 18, 24, and 36 Months
Reported as:
Least squares mean · units on a scale
Change From Baseline POPDI Score
units on a scaleUPHOLDUSLS
6 Months-40.7 (-45.7 to -35.7)-37 (-42.1 to -31.9)
12 Months-41.1 (-46 to -36.1)-37.4 (-42.5 to -32.3)
18 Months-40.3 (-45.3 to -35.3)-37.4 (-42.5 to -32.3)
24 Months-41.2 (-46.3 to -36.2)-38 (-43.1 to -32.8)
36 Months-40.1 (-45.2 to -35)-40.2 (-45.5 to -35)
Other pre-specifiedChange From Baseline UDI Score

The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame:
6, 12, 18, 24, and 36 Months
Reported as:
Least squares mean · units on a scale
Change From Baseline UDI Score
units on a scaleUPHOLDUSLS
6 Months-29.5 (-35.2 to -23.8)-24.8 (-30.7 to -19)
12 Months-29.1 (-34.8 to -23.3)-26.8 (-32.7 to -20.9)
18 Months-27.8 (-33.6 to -22)-26.6 (-32.5 to -20.7)
24 Months-28.4 (-34.3 to -22.6)-27.3 (-33.3 to -21.3)
36 Months-28.3 (-34.2 to -22.4)-28.2 (-34.3 to -22.2)
Other pre-specifiedChange From Baseline PFIQ Score

The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman''s daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame:
6, 12, 18, 24, and 36 Months
Reported as:
Least squares mean · units on a scale
Change From Baseline PFIQ Score
units on a scaleUPHOLDUSLS
6 Months-42.9 (-53.9 to -31.9)-46.7 (-57.9 to -35.5)
12 Months-38.3 (-49.3 to -27.3)-47.4 (-58.7 to -36.2)
18 Months-40.1 (-51.2 to -29.1)-50.1 (-61.4 to -38.8)
24 Months-44 (-55.1 to -32.8)-48.8 (-60.2 to -37.4)
36 Months-43.4 (-54.6 to -32.2)-50.4 (-61.9 to -38.8)
Other pre-specifiedChange From Baseline CRAIQ Score

The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman''s daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame:
6, 12, 18, 24, and 36 Months
Reported as:
Least squares mean · units on a scale
Change From Baseline CRAIQ Score
units on a scaleUPHOLDUSLS
6 Months-6.7 (-10.8 to -2.6)-10.1 (-14.3 to -5.9)
12 Months-4.7 (-8.8 to -0.6)-9.5 (-13.7 to -5.3)
18 Months-4.6 (-8.7 to -0.5)-9.6 (-13.8 to -5.4)
24 Months-7.3 (-11.4 to -3.1)-9.7 (-13.9 to -5.4)
36 Months-6.1 (-10.3 to -1.9)-9.8 (-14.1 to -5.5)
Other pre-specifiedChange From Baseline POPIQ Score

The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman''s daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame:
6, 12, 18, 24, and 36 Months
Reported as:
Least squares mean · units on a scale
Change From Baseline POPIQ Score
units on a scaleUPHOLDUSLS
6 Months-15.7 (-20.6 to -10.9)-18.9 (-23.9 to -13.9)
12 Months-14.6 (-19.4 to -9.7)-19.5 (-24.5 to -14.5)
18 Months-15.9 (-20.8 to -11.1)-20.1 (-25.1 to -15.1)
24 Months-15.9 (-20.8 to -11)-19.1 (-24.1 to -14)
36 Months-16 (-21 to -11.1)-19.9 (-25 to -14.8)
Other pre-specifiedChange From Baseline UIQ Score

The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman''s daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame:
6, 12, 18, 24, and 36 Months
Reported as:
Least squares mean · units on a scale
Change From Baseline UIQ Score
units on a scaleUPHOLDUSLS
6 Months-20.5 (-25.5 to -15.5)-17.7 (-22.8 to -12.6)
12 Months-19 (-24 to -14.1)-18.4 (-23.5 to -13.4)
18 Months-19.5 (-24.5 to -14.6)-20.4 (-25.5 to -15.3)
24 Months-20.8 (-25.8 to -15.7)-20.1 (-25.3 to -15)
36 Months-21.3 (-26.3 to -16.2)-20.6 (-25.8 to -15.4)
Other pre-specifiedChange From Baseline Incontinence Severity Index

Incontinence Severity Index measuring the severity of urinary incontinence is composed of 2 questions: frequency of leakage (0=Never,...,4=Every day/night) and amount of urine leakage (1=Drops, 2=small splashes, 3= More). The index score is calculated categorizing the product of the two responses. The range of responses is: 0 (no incontinence) to 12 (severe incontinence). Lower index scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame:
6, 12, 18, 24, and 36 Months
Reported as:
Least squares mean · units on a scale
Change From Baseline Incontinence Severity Index
units on a scaleUPHOLDUSLS
6 Months-2.4 (-3.2 to -1.6)-1.3 (-2.1 to -0.6)
12 Months-2.1 (-2.9 to -1.3)-1.4 (-2.2 to -0.6)
18 Months-2.1 (-2.9 to -1.3)-1.3 (-2.1 to -0.5)
24 Months-1.9 (-2.7 to -1.2)-1.4 (-2.2 to -0.6)
36 Months-1.9 (-2.7 to -1.1)-1.6 (-2.5 to -0.8)
Other pre-specifiedChange From Baseline Functional Activity Scale

Functional Activity Scale measuring the impact of incontinence symptoms on a woman''s daily activities is composed of 13 questions about normal and physically strenuous daily activities. The range of responses on the individual questions is (1) No difficulty,... (5) Not able to do it. Scores are calculated by subtracting from the maximum sum (5\*13=65) the product of the mean response and number of questions, then dividing by the total range of sums (65 - 13 = 52) and multiplying by 100. The range of responses is: 0-100 with 0 (worse functionality) to 100 (Better functionality). Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame:
6, 12, 18, 24, and 36 Months
Reported as:
Least squares mean · units on a scale
Change From Baseline Functional Activity Scale
units on a scaleUPHOLDUSLS
6 Months6.3 (3.5 to 9)7.7 (4.9 to 10.5)
12 Months6.3 (3.6 to 9.1)6 (3.2 to 8.8)
18 Months5.8 (3 to 8.5)6.6 (3.8 to 9.5)
24 Months4.9 (2.1 to 7.7)6.2 (3.3 to 9)
36 Months5.6 (2.8 to 8.5)4.8 (1.9 to 7.7)
Other pre-specifiedChange From Baseline Body Part Pain Scale

The Body Part Pain Scale measuring the the pain experienced in the lower abdomen and pelvic region of the body is composed of 7 questions, each with a yes (1) or no (0) questions about experiencing pain followed by an intensity rating: 0 (No pain),..., 10 (Most intense). The score is calculated as the average of the responses. The range of responses is: 0-10 with 0 (No pain) to 10 (most intense pain). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame:
6, 12, 18, 24, 30, and 36 Months
Reported as:
Least squares mean · units on a scale
Change From Baseline Body Part Pain Scale
units on a scaleUPHOLDUSLS
6 Months-0.4 (-0.6 to -0.2)-0.3 (-0.5 to -0.1)
12 Months-0.5 (-0.7 to -0.3)-0.3 (-0.5 to -0.1)
18 Months-0.5 (-0.7 to -0.3)-0.3 (-0.5 to -0.1)
24 Months-0.6 (-0.8 to -0.3)-0.3 (-0.6 to -0.1)
30 Months-0.5 (-0.7 to -0.3)-0.3 (-0.5 to -0.1)
36 Months-0.5 (-0.7 to -0.3)-0.3 (-0.5 to -0.1)
Other pre-specifiedChange From Baseline Surgical Pain Scale Rest Score

The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame:
6, 12, 18, 24, and 36 Months
Reported as:
Least squares mean · units on a scale
Change From Baseline Surgical Pain Scale Rest Score
units on a scaleUPHOLDUSLS
6 Months-0.7 (-1.1 to -0.3)-0.8 (-1.2 to -0.3)
12 Months-0.6 (-1 to -0.2)-0.7 (-1.1 to -0.2)
18 Months-0.6 (-1 to -0.2)-0.8 (-1.2 to -0.4)
24 Months-0.7 (-1.2 to -0.3)-0.5 (-0.9 to -0.1)
36 Months-0.5 (-1 to -0.1)-0.6 (-1.1 to -0.2)
Other pre-specifiedChange From Baseline Surgical Pain Scale Normal Score

The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame:
6, 12, 18, 24, and 36 Months
Reported as:
Least squares mean · units on a scale
Change From Baseline Surgical Pain Scale Normal Score
units on a scaleUPHOLDUSLS
6 Months-0.9 (-1.3 to -0.4)-0.8 (-1.3 to -0.4)
12 Months-0.9 (-1.3 to -0.4)-0.8 (-1.3 to -0.4)
18 Months-1 (-1.4 to -0.5)-0.8 (-1.3 to -0.4)
24 Months-1 (-1.4 to -0.5)-0.6 (-1 to -0.1)
36 Months-0.7 (-1.2 to -0.2)-0.7 (-1.2 to -0.2)
Other pre-specifiedChange From Baseline Surgical Pain Scale Exercise Score

The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame:
6, 12, 18, 24, and 36 Months
Reported as:
Least squares mean · units on a scale
Change From Baseline Surgical Pain Scale Exercise Score
units on a scaleUPHOLDUSLS
6 Months-1 (-1.7 to -0.3)-1.4 (-2.1 to -0.6)
12 Months-0.9 (-1.6 to -0.2)-1.1 (-1.8 to -0.4)
18 Months-0.9 (-1.6 to -0.2)-1.2 (-1.9 to -0.5)
24 Months-1 (-1.7 to -0.3)-0.9 (-1.7 to -0.1)
36 Months-1.2 (-2 to -0.5)-0.9 (-1.7 to -0.1)
Other pre-specifiedChange From Baseline Surgical Pain Scale Worst Score

The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).

Time frame:
6, 12, 18, 24, and 36 Months
Reported as:
Least squares mean · units on a scale
Change From Baseline Surgical Pain Scale Worst Score
units on a scaleUPHOLDUSLS
6 Months-0.8 (-1.3 to -0.3)-0.9 (-1.4 to -0.4)
12 Months-1 (-1.5 to -0.5)-0.7 (-1.3 to -0.2)
18 Months-0.9 (-1.5 to -0.4)-0.9 (-1.5 to -0.4)
24 Months-1 (-1.6 to -0.5)-0.6 (-1.2 to 0)
36 Months-0.8 (-1.4 to -0.3)-0.5 (-1.1 to 0)
Other pre-specifiedChange From Baseline Body Image Scale

The Body Image Scale measuring how the subjects feel about their appearance and about any changes that may have resulted from their condition consists of 8 questions. The questions are scored from 0=Not at all,..., 3=Very much. The score is calculated by summing the responses and ranges from 0 to 24. Higher scores correspond to worse body image. Change = Month \[6, 12, 18, 24, and 36\] Score - Baseline Score.

Time frame:
6, 12, 18, 24, and 36 Months
Reported as:
Least squares mean · units on a scale
Change From Baseline Body Image Scale
units on a scaleUPHOLDUSLS
6 Months-5 (-6.1 to -3.8)-3.7 (-4.9 to -2.6)
12 Months-4.9 (-6.1 to -3.7)-3.9 (-5.1 to -2.7)
18 Months-4.8 (-6 to -3.6)-3.9 (-5.1 to -2.7)
24 Months-4.8 (-6 to -3.6)-3.8 (-5 to -2.6)
36 Months-4.9 (-6.1 to -3.7)-3.8 (-5 to -2.6)
Other pre-specifiedChange From Baseline PISQ-IR Sexually Active Average Score

The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR) is a questionnaire measuring the impact of incontinence symptoms on sexual function and satisfaction. The PISQ-IR Sexually Active-Average Score (SA-AVG) ranges from 0 to 5 with higher scores indicating better function/satisfaction. The change from baseline outcome is calculated as the difference in score at 6, 12, 18, 24, and 36 months and the score at baseline.

Time frame:
6, 12, 18, 24, and 36 Months
Reported as:
Least squares mean · units on a scale
Change From Baseline PISQ-IR Sexually Active Average Score
units on a scaleUPHOLDUSLS
6 Months0.2 (0.1 to 0.4)0.3 (0.1 to 0.5)
12 Months0.2 (0 to 0.4)0.3 (0.1 to 0.5)
18 Months0.3 (0.1 to 0.4)0.2 (0.1 to 0.4)
24 Months0.3 (0.1 to 0.5)0.3 (0.2 to 0.5)
36 Months0.3 (0.1 to 0.5)0.3 (0.1 to 0.5)
Other pre-specifiedPOP-Q Ba Measurement

The Pelvic Organ Prolapse Quantification (POPQ) Point Ba represents the most distal (i.e. most dependent) position of any part of the upper anterior vaginal wall (between the vaginal cuff or anterior vaginal fornix and Point Aa). Point Ba coincides with Point Aa (-3 cm) in a woman who has no anterior POP. In a woman with severe POP, Ba coincides with Point C.

Time frame:
12, 24, and 36 Months
Reported as:
Mean · cm
POP-Q Ba Measurement
cmUPHOLDUSLS
12 Months-1.3 (-1.6 to -1)-0.8 (-1.1 to -0.5)
24 Months-1.5 (-1.8 to -1.2)-1.1 (-1.4 to -0.7)
36 Months-1.2 (-1.5 to -0.8)-0.7 (-1 to -0.3)
Other pre-specifiedPOP-Q Bp Measurement

The Pelvic Organ Prolapse Quantification (POPQ) Point Bp represents the most distal position of any part of the upper posterior vaginal wall (between the vaginal cuff or posterior vaginal fornix and Point Ap).

Time frame:
12, 24, and 36 Months
Reported as:
Mean · cm
POP-Q Bp Measurement
cmUPHOLDUSLS
12 Months-1.9 (-2.2 to -1.6)-2 (-2.2 to -1.7)
24 Months-1.8 (-2.1 to -1.5)-2 (-2.2 to -1.8)
36 Months-1.7 (-2.1 to -1.4)-1.8 (-2.1 to -1.5)
Other pre-specifiedPOP-Q C Measurement

The Pelvic Organ Prolapse Quantification (POPQ) Point C is measured in cm relative to the hymen with negative values being proximal to the hymen and positive values distal to the hymen. Point C represents either the most distal edge of the cervix or the leading edge of the vaginal cuff after total hysterectomy.

Time frame:
12, 24, and 36 Months
Reported as:
Mean · cm
POP-Q C Measurement
cmUPHOLDUSLS
12 Months-5.6 (-6.2 to -5)-6.1 (-6.6 to -5.6)
24 Months-6 (-6.4 to -5.5)-6.1 (-6.4 to -5.7)
36 Months-5.7 (-6.2 to -5.1)-5.8 (-6.2 to -5.3)
Other pre-specifiedPOP-Q TVL Measurement

The Pelvic Organ Prolapse Quantification (POPQ) Total Vaginal Length (TVL) is the length of the vagina from posterior fornix tothe hymen when Point C or D is reduced to its full normal position.

Time frame:
12, 24, and 36 Months
Reported as:
Mean · cm
POP-Q TVL Measurement
cmUPHOLDUSLS
12 Months8.5 (8.3 to 8.7)8 (7.7 to 8.2)
24 Months8.6 (8.4 to 8.9)7.8 (7.5 to 8)
36 Months8.5 (8.2 to 8.7)7.7 (7.4 to 8)
Other pre-specifiedPGI-I

The Patient Global Impression of Improvement (PGI-I) is a patient-reported measure of perceived improvement with treatment, as assessed on a scale of 1 (very much better) to 7 (very much worse). Included here are participants who had improvement as indicated by a rating of 1 (very much better), 2 (much better).

Time frame:
6,12, 18, 24, and 36 Months
Reported as:
Count of participants · Participants
PGI-I
ParticipantsUPHOLDUSLS
6 Months — No improvement7981
6 Months — Improved84
12 Months — No improvement7576
12 Months — Improved118
18 Months — No improvement7076
18 Months — Improved127
24 Months — No improvement6971
24 Months — Improved108
36 Months — No improvement7067
36 Months — Improved88

Adverse events

Collected over 36 Months. Non-serious events are listed at a 0.00% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Hysterectomy2/90 (2.2%)10/90 (11.1%)73/90 (81.1%)
Hysteropexy1/93 (1.1%)10/93 (10.8%)73/93 (78.5%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventHysterectomyHysteropexy
ColitisGastrointestinal disorders2/900/93
Stress urinary incontinenceRenal and urinary disorders2/900/93
OsteoarthritisMusculoskeletal and connective tissue disorders0/902/93
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/902/93
Deep vein thrombosisVascular disorders0/902/93
Colitis ischaemicGastrointestinal disorders1/900/93
ConstipationGastrointestinal disorders1/900/93
Diverticular perforationGastrointestinal disorders1/900/93
Post procedural haemorrhageInjury, poisoning and procedural complications1/900/93
Musculoskeletal painMusculoskeletal and connective tissue disorders1/900/93
Most frequent other events
Showing 10 of 93
Most frequent other events
EventHysterectomyHysteropexy
Urinary tract infectionInfections and infestations39/9034/93
Stress urinary incontinenceRenal and urinary disorders11/9019/93
Urge incontinenceRenal and urinary disorders13/9019/93
Suture exposure after 12 wks.Injury, poisoning and procedural complications17/903/93
ConstipationGastrointestinal disorders13/905/93
Excessive granulation tissue after 12 wks.Skin and subcutaneous tissue disorders10/901/93
Faecal incontinenceGastrointestinal disorders4/9010/93
Ureteric kinkInjury, poisoning and procedural complications7/900/93
Urinary retentionRenal and urinary disorders7/906/93
Pelvic painReproductive system and breast disorders7/903/93

Baseline characteristics

The baseline analysis population comprises all randomized participants that received the assigned intervention and were determined to still be eligible for the intervention after review of the initial POP-Q and PFDI-20.

Age, Continuous
Age, Continuous(years)UPHOLDUSLSTotal
Mean65.5 ± 766.2 ± 765.9 ± 7
Sex/Gender, Customized
Sex/Gender, Customized(Participants)UPHOLDUSLSTotal
Female8887175
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)UPHOLDUSLSTotal
American Indian/Alaskan Native044
Asian213
Black/African American8311
More than one race011
Other516
White7377150
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)UPHOLDUSLSTotal
Hispanic/Latina9716
Not Hispanic/Not Latina7678154
Unknown/Not Reported325
Marital Status
Marital Status(Participants)UPHOLDUSLSTotal
Divorced, separated161329
Married/Living with partner5658114
Single9716
Widowed7916
Education
Education(Participants)UPHOLDUSLSTotal
4-year College Degree162036
Associate College Degree221941
Graduate Degree111526
High School/GED312657
Less than High School6511
Unknown/Not Reported224
Body Mass Index
Body Mass Index(kg/m^2)UPHOLDUSLSTotal
Mean28.9 ± 4.028.2 ± 4.428.5 ± 4.2
Current Smoker
Current Smoker(Participants)UPHOLDUSLSTotal
No8586171
Yes314

8 further baseline measures are reported on the registry.

08

Study locations

8 sites
  • University of Alabama at Birmingham, Department of Obstetrics and Gynecology
    Birmingham, Alabama 35249, United States
  • University of California at San Diego, UCSD Women's Pelvic Medicine Center
    La Jolla, California 92037-0974, United States
  • University of New Mexico Health Sciences Center, Department of Obstetrics and Gynecology
    Albuquerque, New Mexico 87131, United States
  • Duke University, Duke Division of Urogynecology and Reconstructive Pelvic Surgery
    Durham, North Carolina 27707, United States
  • Cleveland Clinic, Department OB/GYN
    Cleveland, Ohio 44195, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Magee-Women's Hospital, Department of Obstetrics and Gynecology
    Pittsburgh, Pennsylvania 15213, United States
  • Brown/ Women and Infants Hospital of Rhode Island, Center for Women's Pelvic Medicine and Reconstructive Surgery
    Providence, Rhode Island 02903, United States
09

References and documents

Publications

  • Nager CW, Visco AG, Richter HE, Rardin CR, Meriwether K, Harvie HS, Zyczynski HM, Paraiso MFR, Mazloomdoost D, Sridhar A, Thomas S; Eunice Kennedy Shriver NICHD Pelvic Floor Disorders Network. Sacrospinous Hysteropexy With Mesh vs Vaginal Hysterectomy for Treatment of Uterovaginal Prolapse: 10-Year Results of a Randomized Clinical Trial. JAMA Surg. 2026 Jun 24:e262263. doi: 10.1001/jamasurg.2026.2263. Online ahead of print. PubMed 42340704 ↗
  • Lockhart ME, Moalli PA, Richter HE, Meyer I, Weidner AC, Komesu YM, Carper B, Gantz MG; Eunice Kennedy Shriver NICHD Pelvic Floor Disorders Network. MRI 2-D Parameters Associated with Native Tissue or Transvaginal Mesh Surgical Apical Prolapse Repair Failure. Int Urogynecol J. 2026 May 30. doi: 10.1007/s00192-026-06699-0. Online ahead of print. PubMed 42217015 ↗
  • Bradley MS, Sridhar A, Ferrante K, Andy UU, Visco AG, Florian-Rodriguez ME, Myers D, Varner E, Mazloomdoost D, Gantz MG; NICHD Pelvic Floor Disorders Network. Association Between Enlarged Genital Hiatus and Composite Surgical Failure After Vaginal Hysterectomy With Uterosacral Ligament Suspension. Urogynecology (Phila). 2023 May 1;29(5):479-488. doi: 10.1097/SPV.0000000000001309. Epub 2022 Dec 23. PubMed 36701331 ↗
  • Napoe GS, Luchristt D, Sridhar A, Ellington D, Ridgeway B, Mazloomdoost D, Sung V, Ninivaggio C, Harvie H, Santiago-Lastra Y, Gantz MG, Zyczynski HM. Reoperation for prolapse recurrence after sacrospinous mesh hysteropexy: characteristics of women choosing retreatment. Int Urogynecol J. 2023 Jan;34(1):255-261. doi: 10.1007/s00192-022-05411-2. Epub 2022 Nov 30. PubMed 36449027 ↗
  • Nager CW, Visco AG, Richter HE, Rardin CR, Komesu Y, Harvie HS, Zyczynski HM, Paraiso MFR, Mazloomdoost D, Sridhar A, Thomas S; National Institute of Child Health and Human Development Pelvic Floor Disorders Network. Effect of sacrospinous hysteropexy with graft vs vaginal hysterectomy with uterosacral ligament suspension on treatment failure in women with uterovaginal prolapse: 5-year results of a randomized clinical trial. Am J Obstet Gynecol. 2021 Aug;225(2):153.e1-153.e31. doi: 10.1016/j.ajog.2021.03.012. Epub 2021 Mar 12. PubMed 33716071 ↗
  • Lukacz ES, Sridhar A, Chermansky CJ, Rahn DD, Harvie HS, Gantz MG, Varner RE, Korbly NB, Mazloomdoost D; Eunice Kennedy Shriver National Institute of Child Health and Human Development Pelvic Floor Disorders Network (PFDN). Sexual Activity and Dyspareunia 1 Year After Surgical Repair of Pelvic Organ Prolapse. Obstet Gynecol. 2020 Sep;136(3):492-500. doi: 10.1097/AOG.0000000000003992. PubMed 32769645 ↗
  • Nager CW, Visco AG, Richter HE, Rardin CR, Rogers RG, Harvie HS, Zyczynski HM, Paraiso MFR, Mazloomdoost D, Grey S, Sridhar A, Wallace D; NICHD Pelvic Floor Disorders Network. Effect of Vaginal Mesh Hysteropexy vs Vaginal Hysterectomy With Uterosacral Ligament Suspension on Treatment Failure in Women With Uterovaginal Prolapse: A Randomized Clinical Trial. JAMA. 2019 Sep 17;322(11):1054-1065. doi: 10.1001/jama.2019.12812. PubMed 31529008 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2013 to primary completion in Jul 2023, 123 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2013
First posted
Mar 1, 2013
StartActual
Apr 1, 2013
Primary completionActual
Jul 31, 2023
CompletionActual
Mar 7, 2025
Results first posted
Mar 22, 2021
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01802281
Lead sponsor
NICHD Pelvic Floor Disorders Network
Responsible party
Sponsor
First posted
Mar 1, 2013
Start date
Apr 1, 2013
Primary completion
Jul 31, 2023
Completion
Mar 7, 2025
Results posted
Mar 22, 2021
Last update
Aug 26, 2025

Study contacts

Charles W Nager, MD
principal investigator · University of California at San Diego, UCSD Women's Pelvic Medicine Center
Anthony G Visco, MD
principal investigator · Duke University, Duke Division of Urogynecology and Reconstructive Pelvic Surgery
Heidi Harvie, MD
principal investigator · University of Pennsylvania
Marie Paraiso, MD
principal investigator · Cleveland Clinic, Department OB/GYN
Charles R Rardin, MD
principal investigator · Brown/ Women and Infants Hospital of Rhode Island, Center for Women's Pelvic Medicine and Reconstructive Surgery
Holly E Richter, PhD, MD
principal investigator · University of Alabama at Birmingham, Department of Obstetrics and Gynecology
Kate Meriwether, MD
principal investigator · University of New Mexico Health Sciences Center, Department of Obstetrics and Gynecology
Halina M Zyczynski, MD
principal investigator · Magee-Women's Hospital, Department of Obstetrics and Gynecology
Sonia Thomas, DrPH
principal investigator · RTI International

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion